MacroGenics Inc. (NASDAQ:MGNX)’s share price was up 2.2% during trading on Friday . The company traded as high as $27.15 and last traded at $27.04, with a volume of 153,280 shares. The stock had previously closed at $26.46.

A number of equities analysts have commented on MGNX shares. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of MacroGenics in a research note on Tuesday, June 14th. Morgan Stanley reissued a “hold” rating on shares of MacroGenics in a research note on Thursday, June 30th. BTIG Research started coverage on shares of MacroGenics in a research note on Thursday, April 7th. They issued a “buy” rating and a $35.00 price objective for the company. Leerink Swann reissued an “outperform” rating and issued a $47.00 price objective on shares of MacroGenics in a research note on Thursday, May 19th. Finally, Wedbush reissued an “outperform” rating and issued a $52.00 price objective on shares of MacroGenics in a research note on Wednesday, May 18th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $40.25.

The firm’s 50 day moving average price is $26.01 and its 200 day moving average price is $21.51. The company’s market capitalization is $941.01 million.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.21. Equities research analysts forecast that MacroGenics Inc. will post ($2.29) earnings per share for the current fiscal year.

In other news, VP Lynn Cilinski sold 8,922 shares of the stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $27.22, for a total value of $242,856.84. Following the completion of the sale, the vice president now directly owns 10,845 shares in the company, valued at $295,200.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Jon Marc Wigginton sold 5,000 shares of the stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $27.22, for a total transaction of $136,100.00. Following the completion of the sale, the chief marketing officer now owns 5,000 shares of the company’s stock, valued at $136,100. The disclosure for this sale can be found here.

Several large investors have modified their holdings of MGNX. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock worth $1,386,000 after buying an additional 20,929 shares during the period. California State Teachers Retirement System boosted its stake in shares of MacroGenics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 58,401 shares of the biopharmaceutical company’s stock worth $1,809,000 after buying an additional 1,038 shares during the period. GAM Holding AG boosted its stake in shares of MacroGenics by 118.3% in the fourth quarter. GAM Holding AG now owns 63,100 shares of the biopharmaceutical company’s stock worth $1,954,000 after buying an additional 34,200 shares during the period. Marshall Wace LLP boosted its stake in shares of MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock worth $2,902,000 after buying an additional 45,422 shares during the period. Finally, Jennison Associates LLC boosted its stake in shares of MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock worth $8,282,000 after buying an additional 909 shares during the period.

MacroGenics, Inc is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.